MassMutual Private Wealth & Trust FSB Boosts Stake in Qiagen (NYSE:QGEN)

MassMutual Private Wealth & Trust FSB increased its stake in Qiagen (NYSE:QGEN) by 83.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,565 shares of the company’s stock after acquiring an additional 712 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Qiagen were worth $70,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in shares of Qiagen by 77.7% in the 3rd quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock worth $963,386,000 after purchasing an additional 9,293,040 shares in the last quarter. Barclays PLC lifted its position in Qiagen by 170.6% in the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after buying an additional 1,165,594 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Qiagen by 62.6% in the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after buying an additional 991,325 shares in the last quarter. Point72 Asset Management L.P. grew its position in Qiagen by 148.8% during the second quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock valued at $48,684,000 after acquiring an additional 708,533 shares during the last quarter. Finally, Point72 DIFC Ltd raised its stake in shares of Qiagen by 10,610.4% during the third quarter. Point72 DIFC Ltd now owns 649,693 shares of the company’s stock worth $29,606,000 after acquiring an additional 643,627 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of QGEN stock opened at $45.86 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.93. The firm has a market cap of $10.47 billion, a P/E ratio of 117.59, a P/E/G ratio of 3.51 and a beta of 0.37. The business’s 50 day moving average price is $44.43 and its 200-day moving average price is $44.22.

Analyst Upgrades and Downgrades

QGEN has been the subject of a number of research reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $48.00 price objective (down previously from $50.00) on shares of Qiagen in a research note on Monday, January 6th. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 17th. Jefferies Financial Group reissued a “buy” rating and issued a $54.00 target price (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.50.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.